Mexico Launches Integrated Patent–Regulatory Platform for Pharmaceuticals

By Goodrich, Riquelme y Asociados

Mexico has introduced a new digital platform aimed at strengthening the intersection between patent protection and pharmaceutical regulation, a longstanding point of friction in the country’s intellectual property framework. The initiative, jointly developed by the Mexican Institute of Industrial Property (IMPI) and the Federal Commission for the Protection against Sanitary Risk (COFEPRIS), creates a centralized technological system linking patent data with sanitary (marketing) authorizations for medicines and health products.

The platform—referred to as the IMPI–COFEPRIS linkage system portal—enables public access to information on patents and their relationship to sanitary registrations, including data on validity, ownership, and associated regulatory approvals. This integration is particularly relevant in the pharmaceutical sector, where regulatory authorities must ensure that marketing approvals do not conflict with existing patent rights.

In practical terms, the system addresses the so-called “linkage mechanism,” a regulatory process designed to prevent the approval of generic medicines that would infringe valid patents. Under this framework, COFEPRIS—Mexico’s health regulatory authority responsible for overseeing drugs, medical devices, and other health-related products—must consult IMPI before granting marketing authorization to confirm whether a patent remains in force.

Historically, this coordination has been criticized for lack of transparency and procedural clarity, leading to delays, inconsistent decisions, and frequent litigation between originator companies and generic manufacturers. The new platform seeks to standardize and digitize this interaction by making key data accessible and traceable, reducing uncertainty for both patent holders and applicants seeking sanitary approval.

The portal also allows users to review the status of patents—whether active, expired, or nearing expiration—as well as submissions and positions from third parties in the regulatory process. This level of visibility is expected to facilitate strategic decision-making for pharmaceutical companies, particularly in planning generic entry timelines and assessing freedom to operate.

From an intellectual property perspective, the initiative reflects a broader trend toward regulatory transparency and digitalization in IP enforcement mechanisms. By aligning patent information with regulatory approval processes, the system reinforces exclusivity rights while providing clearer pathways for lawful market entry once patent protection lapses.

Mexican authorities have also emphasized the platform’s role in supporting public procurement and healthcare planning, as it enables stakeholders to identify which products are protected, when exclusivity expires, and how this aligns with the availability of alternative treatments